Citation Impact
Citing Papers
Selective targeting of engineered T cells using orthogonal IL-2 cytokine-receptor complexes
2018 StandoutScienceNobel
High-throughput characterization of protein–protein interactions by reprogramming yeast mating
2017 StandoutNobel
A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis
2021 StandoutScienceNobel
Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma
2003 StandoutNobel
BAR Domains as Sensors of Membrane Curvature: The Amphiphysin BAR Structure
2003 Science
Recognition of a Ubiquitous Self Antigen by Prostate Cancer-Infiltrating CD8 + T Lymphocytes
2008 StandoutScienceNobel
Selective blockade of inhibitory Fcγ receptor enables human dendritic cell maturation with IL-12p70 production and immunity to antibody-coated tumor cells
2005 StandoutNobel
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells
2016
Programmed cell death 1 ligand 1 and tumor-infiltrating CD8 + T lymphocytes are prognostic factors of human ovarian cancer
2007 StandoutNobel
Designed protein logic to target cells with precise combinations of surface antigens
2020 StandoutScienceNobel
Aire-Dependent Thymic Development of Tumor-Associated Regulatory T Cells
2013 StandoutScienceNobel
PD-1 Is a Regulator of NY-ESO-1-Specific CD8+ T Cell Expansion in Melanoma Patients
2009
Combinatorial Cancer Immunotherapy
2006
Activation of Low Avidity CTL Specific for a Self Epitope Results in Tumor Rejection But Not Autoimmunity
1998
T cell defined tumor antigens
1997
Progress in human tumour immunology and immunotherapy
2001 Nature
Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma
1998 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Strategies to overcome immune ignorance and tolerance
2002
Physical Principles of Membrane Shape Regulation by the Glycocalyx
2019 StandoutNobel
The biology and management of non-small cell lung cancer
2018 StandoutNature
Anaplastic lymphoma kinase proteins in growth control and cancer
2004
Immunology and immunotherapy approaches for prostate cancer
2007
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Regulatory T Cells and Immune Tolerance
2008 StandoutNobel
Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues
2001
Vaccination of melanoma patients with peptide- or tumorlysate-pulsed dendritic cells
1998 Standout
Human tumor antigens recognized by T-cells
1997
Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909
2005
Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen
2006
Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1
2008
Identification of Multiple Antigens Recognized by Tumor-Infiltrating Lymphocytes From a Single Patient: Tumor Escape by Antigen Loss and Loss of MHC Expression
2004
Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
2002
Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy
2014
Microbial Stimulation Fully Differentiates Monocytes to DC-SIGN/CD209+ Dendritic Cells for Immune T Cell Areas
2010 StandoutNobel
Natural selection of tumor variants in the generation of “tumor escape” phenotypes
2002
Phase I/II trial of a dendritic cell vaccine transfected with DNA encoding melan A and gp100 for patients with metastatic melanoma
2011
Tumor‐specific shared antigenic peptides recognized by human T cells
2002
Detection and quantification of CD8+ T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-?-elispot assay
2001
Immunity, Inflammation, and Cancer
2010 Standout
Tumor‐reactive CD8+ T‐cell responses after vaccination with NY‐ESO‐1 peptide, CpG 7909 and Montanide® ISA‐51: association with survival
2009
Human tumor antigens for cancer vaccine development
1999
Taking dendritic cells into medicine
2007 StandoutNatureNobel
Serological identification of breast cancer-related antigens from aSaccharomyces cerevisiae surface display library
2005
In vivo antigen delivery by aSalmonella typhimurium type III secretion system for therapeutic cancer vaccines
2006
Sar1p N-Terminal Helix Initiates Membrane Curvature and Completes the Fission of a COPII Vesicle
2005 StandoutNobel
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell–mediated immunotherapy
2004
NY‐ESO‐1: Review of an Immunogenic Tumor Antigen
2006
Restoring function in exhausted CD8 T cells during chronic viral infection
2005 StandoutNatureNobel
A New Era for Cancer Immunotherapy Based on the Genes that Encode Cancer Antigens
1999
Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting
2012 StandoutNatureNobel
Humoral immune responses of cancer patients against “Cancer-Testis” antigen NY-ESO-1: Correlation with clinical events
1999
Dendritic cells and the control of immunity
1998 StandoutNatureNobel
Cancer-related inflammation
2008 StandoutNature
Adoptive-cell-transfer therapy for the treatment of patients with cancer
2003
Dependence of T Cell Antigen Recognition on T Cell Receptor-Peptide MHC Confinement Time
2010
The Immunobiology of Cancer Immunosurveillance and Immunoediting
2004 Standout
Escape of Human Solid Tumors from T–Cell Recognition: Molecular Mechanisms and Functional Significance
1999
Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand.
2000
In vivoblockade of CTLA-4 enhances the priming of responsive T cells but fails to prevent the induction of tumor antigen-specific tolerance
1999 StandoutNobel
Monitoring CD8 T cell responses to NY-ESO-1: Correlation of humoral and cellular immune responses
2000
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
2006 StandoutScience
Detection of self-reactive CD8 + T cells with an anergic phenotype in healthy individuals
2014 StandoutScienceNobel
SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
2008 StandoutNobel
High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals
1999
Induction of cellular immunity by immunization with novel hybrid peptides complexed to heat shock protein 70
2000 StandoutNobel
Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells
1998
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8 + T cells in a spectrum of human MHC I haplotypes
2007 StandoutNobel
Tumor immune escape mechanisms: impact of the neuroendocrine system
2006
CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients
2005
Natural Innate and Adaptive Immunity to Cancer
2011 Standout
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Structural and kinetic basis for heightened immunogenicity of T cell vaccines
2005
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
Analysis of the B‐cell repertoire against antigens expressed by human neoplasms
2002
Lack of terminally differentiated tumor-specific CD8+ T cells at tumor site in spite of antitumor immunity to self-antigens in human metastatic melanoma.
2003
Increased Antigen Presentation Efficiency by Coupling Antigens to MHC Class I Trafficking Signals
2008
Utilizing the adjuvant properties of CD1d-dependent NK T cells in T cell–mediated immunotherapy
2004
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Identification of a promiscuous T-cell epitope encoded by multiple members of the MAGE family.
1999
IFN-γ enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation
2004
The PD-1/PD-L1 complex resembles the antigen-binding Fv domains of antibodies and T cell receptors
2008 StandoutNobel
Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
2008 StandoutNobel
Influence of CD4+CD25+ Regulatory T Cells on Low/High-Avidity CD4+ T Cells following Peptide Vaccination
2006
Foxp3+natural regulatory T cells preferentially form aggregates on dendritic cellsin vitroand actively inhibit their maturation
2008 StandoutNobel
A Survey of the Humoral Immune Response of Cancer Patients to a Panel of Human Tumor Antigens
1998
Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients
2003 StandoutNobel
CD4+T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production
2001
Mage-3 and Influenza-Matrix Peptide-Specific Cytotoxic T Cells Are Inducible in Terminal Stage HLA-A2.1+ Melanoma Patients by Mature Monocyte-Derived Dendritic Cells
2000
Glycolipid α-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice
2006 StandoutNobel
Does the Immune System See Tumors as Foreign or Self?
2003
Dendritic Cells as Adjuvants for Immune-mediated Resistance to Tumors
1997 StandoutNobel
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Carcinoma Cell Hyaluronan as a “Portable” Cancerized Prometastatic Microenvironment
2016
Identification of tumor antigens as potential target antigens for immunotherapy by serological expression cloning
2004
Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations
2002
Autoantibodies frequently detected in patients with aplastic anemia
2003
PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors
2010 StandoutNobel
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
2006
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
2008 StandoutNobel
Immunotherapy: Bewitched, Bothered, and Bewildered No More
2004 StandoutScienceNobel
Adoptive T cell therapy using antigen-specific CD8+T cell clones for the treatment of patients with metastatic melanoma:In vivopersistence, migration, and antitumor effect of transferred T cells
2002
Antigen Presentation and T Cell Stimulation by Dendritic Cells
2002
Intratumoral T-Cell Infiltrates and MHC Class I Expression in Patients with Stage IV Melanoma
2005
Serological analysis of human tumor antigens: molecular definition and implications
1997
Point Mutation in Essential Genes with Loss or Mutation of the Second Allele
2001
Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancers
2000
Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade
2002 StandoutNobel
Distinct influences of peptide-MHC quality and quantity on in vivo T-cell responses
2012 StandoutNobel
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Identification of Ny-Eso-1 Epitopes Presented by Human Histocompatibility Antigen (Hla)-Drb4*0101–0103 and Recognized by Cd4+T Lymphocytes of Patients with Ny-Eso-1–Expressing Melanoma
2000
Survey of naturally occurring CD4 + T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses
2003
Works of Mark Ringhoffer being referenced
mRNA expression of leukemia‐associated antigens in patients with acute myeloid leukemia for the development of specific immunotherapies
2003
Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptidesin vivo: Implications for tumor vaccines with melanoma-associated antigens
1996
Characterization of several leukemia‐associated antigens inducing humoral immune responses in acute and chronic myeloid leukemia
2003
Inverse relationship of melanocyte differentiation antigen expression in melanoma tissues and CD8+ cytotoxic-T-cell responses: Evidence for immunoselection of antigen-loss variantsin vivo
1996
Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma
1997
Receptor for hyaluronan acid–mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia
2002
Generation of cytotoxic T‐cell responses with synthetic melanoma‐associated peptides in vivo: Implications for tumor vaccines with melanoma‐associated antigens
1996
Granulocyte-macrophage-colony-stimulating factor enhances immune responses to melanoma-associated peptidesin vivo
1996
RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses
2007
Simultaneous Humoral and Cellular Immune Response against Cancer–Testis Antigen NY-ESO-1: Definition of Human Histocompatibility Leukocyte Antigen (HLA)-A2–binding Peptide Epitopes
1998
Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals
1996